Surrozen (NASDAQ:SRZN) Major Shareholder Purchases $236,551.77 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 11,893 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average price of $19.89 per share, with a total value of $236,551.77. Following the completion of the transaction, the insider directly owned 1,005,732 shares of the company’s stock, valued at $20,004,009.48. This trade represents a 1.20% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III bought 18,052 shares of Surrozen stock. The stock was acquired at an average price of $19.60 per share, for a total transaction of $353,819.20.
• On Friday, January 16th, Group Gp Lp Column III purchased 2,562 shares of Surrozen stock. The shares were acquired at an average price of $20.00 per share, with a total value of $51,240.00.
• On Wednesday, January 14th, Group Gp Lp Column III acquired 5,523 shares of Surrozen stock. The shares were acquired at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III acquired 12,470 shares of Surrozen stock. The stock was bought at an average price of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III bought 15,100 shares of Surrozen stock. The shares were bought at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The shares were bought at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The stock was bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III purchased 315,457 shares of Surrozen stock. The shares were purchased at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Trading Up 4.3%

SRZN stock opened at $20.00 on Friday. The business’s fifty day moving average price is $19.26 and its 200 day moving average price is $14.21. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $24.94. The company has a market capitalization of $171.40 million, a PE ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Research analysts predict that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SRZN. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Investors Weigh In On Surrozen

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Stonepine Capital Management LLC increased its holdings in Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the last quarter. Stempoint Capital LP raised its stake in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares in the last quarter. Armistice Capital LLC purchased a new stake in Surrozen during the 2nd quarter worth about $536,000. Finally, Braidwell LP acquired a new position in shares of Surrozen during the 2nd quarter worth about $1,252,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.